Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

2026 American Academy of Dermatology (AAD)

 Annual Meeting arrives at a pivotal moment for the field, with a slate of late-breaking data poised to reshape treatment paradigms across some of dermatology's most challenging conditions.

From atopic dermatitis and plaque psoriasis to hidradenitis suppurativa (HS) and dermatomyositis, this year's program is headlined by phase 3 readouts that represent years of clinical development, and in several cases, potential first-in-class approvals that could redefine the standard of care.

Taken together, the sessions reflect a broader maturation of the dermatology pipeline, one increasingly defined by oral precision therapies, novel biologic mechanisms, and a growing willingness to tackle rare and historically underserved diseases head-on.

Efficacy and Safety of Monotherapy Amlitelimab, a Non-Depleting Anti-OX40 Ligand Antibody, in Moderate-to-Severe Atopic Dermatitis: 24-Week Results From the Pivotal COAST 1 and COAST 2 Phase 3 Trials and Efficacy and Safety of Amlitelimab, a Non-Depleting Anti-OX40 Ligand Antibody, in Combination With Topical Therapy in Participants With Moderate-to-Severe Atopic Dermatitis: 24-Week Results From the SHORE Phase 3 Trial

Presenter: Eric Lawrence Simpson, MD, FAAD

Sanofi’s amlitelimab, a non-depleting anti-OX40 ligand monoclonal antibody, consolidates 24-week data from three pivotal phase 3 studies. COAST 1 (n=601) met all primary and key secondary endpoints across Q4W and Q12W dosing. SHORE met all EU estimand primary and key secondary endpoints in combination with topical corticosteroids. COAST 2 met the US estimand co-primary endpoint, narrowly missing EU co-primary endpoints.

 Global regulatory submissions are planned for H2 2026.

Efficacy and Safety of Abrocitinib in Patients with Chronic Hand Eczema: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial

Presenter: Robert Bissonnette, MSc, MD, FAAD

Pfizer’s abrocitinib (Cibinqo), an oral selective JAK1 inhibitor approved for moderate-to-severe atopic dermatitis, presents phase 3 results from the first randomized, placebo-controlled trial dedicated to chronic hand eczema (CHE). Prior phase 2b data (HAWK) established proof-of-concept for JAK1 inhibition in CHE.

 A positive outcome would support a label expansion for Cibinqo, positioning abrocitinib as the first oral JAK inhibitor with dedicated pivotal evidence in this indication. AAD 2026 marks the first public disclosure of the full trial results.

Envudeucitinib (ESK-001) in moderate-to-severe plaque psoriasis: 24-week results from the randomized, double-blind, active comparator- and placebo-controlled, Phase 3 ONWARD 1 and 2 studies

Alumis’ envudeucitinib, a highly selective oral TYK2 inhibitor, met all co-primary and ranked secondary endpoints in both phase 3 ONWARD studies (total n > 1,700), with superiority over placebo and apremilast (

< .0001). Across both trials, 74% of patients achieved PASI 75 at week 16; by week 24, approximately 65% achieved PASI 90 and more than 40% achieved PASI 100, with no new safety signals.

 Full 24-week data will be presented publicly for the first time at AAD 2026. An NDA filing is planned for H2 2026.

Efficacy and Safety of Upadacitinib in Adolescents and Adults for Treatment of Non-Segmental Vitiligo: Results of Two Phase 3 Studies (Viti-Up)

AbbVie’s upadacitinib (Rinvoq) 15 mg once daily met both co-primary endpoints across two replicate phase 3 Viti-Up studies (combined n≈614) in adults and adolescents ≥12 years with non-segmental vitiligo. T-VASI 50 at week 48 was achieved by 19.4% and 21.5% of treated patients versus 5.9% on placebo; F-VASI 75 by 25.2% and 23.4% versus 5.9% and 6.9%.

 Regulatory submissions have been filed with the FDA and EMA. If approved, upadacitinib would be the first systemic therapy indicated for vitiligo.

Concomitant therapy with ixekizumab plus tirzepatide in adults with psoriatic arthritis and overweight or obesity demonstrated superior disease control compared to ixekizumab alone: results from the Ph3b TOGETHER-PsA trial

Eli Lilly’s TOGETHER-PsA is the first randomized trial to test whether co-treating obesity alongside a biologic improves psoriatic arthritis outcomes. In the phase 3b study (n=271), 31.7% of patients receiving ixekizumab (Taltz) plus tirzepatide (Zepbound) achieved the composite primary endpoint of ACR50 plus ≥10% weight reduction at week 36 versus 0.8% on ixekizumab alone (

< .001). ACR50 alone also favored the combination (33.5% vs. 20.4%; 

Once-daily Oral Zasocitinib Demonstrates Rapid and Reproducible Skin Clearance with a Consistent Safety Profile in Moderate-to-Severe Plaque Psoriasis: Results from Two Randomized Phase 3 Trials (LATITUDE-PsO-3001 and 3002)

Takeda’s zasocitinib, an oral once-daily TYK2 inhibitor with more than one-million-fold selectivity for TYK2 over other JAK enzymes, met all primary and all 44 ranked secondary endpoints in both phase 3 LATITUDE studies (n=693 and n=1108), with superiority over placebo and apremilast. More than half of treated patients achieved PASI 90 and approximately 30% achieved PASI 100 at week 16.

 Full 24-week data will be presented for the first time at AAD 2026. Takeda plans to file an NDA in fiscal year 2026.

Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies

Incyte’s povorcitinib (INCB54707), a selective oral JAK1 inhibitor, met the primary endpoint of HiSCR50 at week 12 in both phase 3 STOP-HS studies (~600 patients each), with 40.2–42.3% responding versus 28.6–29.7% on placebo.

 The 54-week dataset at AAD 2026 represents the most comprehensive durability evidence yet for any oral therapy in hidradenitis suppurativa, and is expected to support Incyte’s planned US regulatory submission in early 2026. No MACE events or deaths were observed through week 24.

Sonelokimab in moderate-to-severe HS: Long-term results through Week 40 of two Phase 3 trials

Presenter: Alexandra Boer Kimball, MD, MPH, FAAD

MoonLake Immunotherapeutics’ sonelokimab, a trivalent Nanobody targeting IL-17A and IL-17F, will present long-term data through week 40 from the VELA phase 3 program (n=838). VELA was the first phase 3 HS program to use HiSCR75 as its primary endpoint. VELA-1 met statistical significance at week 16; VELA-2 narrowly missed, attributed to an elevated placebo response.

 The week 40 data at AAD 2026 — the longest follow-up from any phase 3 HS trial — are pivotal for assessing durability and informing MoonLake’s regulatory path.

Brepocitinib Achieves Rapid and Sustained Control of Cutaneous Disease Activity, Itch, and Skin-Related Quality of Life in Dermatomyositis: Results From the Phase 3 VALOR Trial

Presenter: Ruth Ann Vleugels, MD, MBA, MPH, FAAD

Priovant Therapeutics’ brepocitinib, an oral dual TYK2/JAK1 inhibitor, is the first therapy to demonstrate efficacy in a randomized, placebo-controlled phase 3 trial in dermatomyositis. VALOR (n=241) met its primary endpoint with a mean Total Improvement Score of 46.5 versus 31.2 for placebo at week 52 (

= .0006), with all nine key secondary endpoints met and steroid-sparing effects demonstrated.

 The FDA has accepted the NDA and granted Priority Review. If approved, brepocitinib would be the first targeted therapy for dermatomyositis.

Sanofi. Sanofi’s amlitelimab confirms its potential in atopic dermatitis. GlobeNewswire. Published January 23, 2026. Accessed March 18, 2026. 

https://www.globenewswire.com/news-release/2026/01/23/3224400/0/en/Press-Release-Sanofi-s-amlitelim…

King B, Silverberg JI, Gimenez-Arnau AM, et al. Abrocitinib monotherapy in adults with chronic hand eczema (HAWK): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2023;401(10386):1423-1434. Accessed March 18, 2026. 

https://doi.org/10.1016/S0140-6736(23)00296-X

Alumis Inc. Alumis’ envudeucitinib delivers leading skin clearance among next-generation oral plaque psoriasis therapies in phase 3 program. BusinessWire. Published January 6, 2026. Accessed March 18, 2026. 

https://investors.alumis.com/news-releases/news-release-details/alumis-envudeucitinib-delivers-lead…

AbbVie Inc. AbbVie announces positive topline results from phase 3 pivotal studies evaluating upadacitinib (RINVOQ) in adults and adolescents with vitiligo. Published October 29, 2025. Accessed March 18, 2026. 

https://news.abbvie.com/2025-10-29-AbbVie-Announces-Positive-Topline-Results-from-Phase-3-Pivotal-S…

Eli Lilly and Company. Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together demonstrated superior disease control compared to ixekizumab alone: results from the Ph3b TOGETHER-PsA trial. Published January 8, 2026. Accessed March 18, 2026. 

https://investor.lilly.com/news-releases/news-release-details/lillys-taltz-ixekizumab-and-zepbound-…

Takeda Pharmaceutical Company. Takeda’s zasocitinib delivers landmark data from two phase 3 studies in plaque psoriasis. Published December 18, 2025. Accessed March 18, 2026. 

https://www.takeda.com/newsroom/newsreleases/2025/takeda-zasocitinib-phase-3-plaque-psoriasis-data-…

Incyte Corporation. Incyte announces positive topline results from two phase 3 clinical trials of povorcitinib in patients with hidradenitis suppurativa. BusinessWire. Published March 17, 2025. Accessed March 18, 2026. 

https://www.businesswire.com/news/home/20250317947508/en/Incyte-Announces-Positive-Topline-Results-…

MoonLake Immunotherapeutics AG. MoonLake announces topline results from the VELA phase 3 program evaluating sonelokimab in hidradenitis suppurativa. GlobeNewswire. Published 2025. Accessed March 18, 2026. 

Roivant Sciences Ltd / Priovant Therapeutics Inc. Roivant and Priovant announce positive phase 3 VALOR study results for brepocitinib in dermatomyositis. GlobeNewswire. Published September 17, 2025. Accessed March 18, 2026. 

https://investor.roivant.com/news-releases/news-release-details/roivant-and-priovant-announce-posit…

Articles

Late-breaking phase 3 datasets at AAD 2026 underscore a dermatology pipeline shifting toward oral precision immunomodulators, differentiated biologic mechanisms, and expansion into underserved indications. Key readouts include anti–OX40L amlitelimab in atopic dermatitis with mixed US/EU estimand success, and new pivotal evidence for abrocitinib in chronic hand eczema. Multiple oral TYK2 programs (envudeucitinib, zasocitinib) report high PASI90/100 rates versus placebo and apremilast. Additional highlights include systemic upadacitinib for vitiligo, obesity co-therapy improving PsA control, durable HS datasets, and a first positive phase 3 dermatomyositis trial with brepocitinib.

This preview highlights key data to watch out for during the 2026 American Academy of Dermatology (AAD) meeting in Denver, Colorado.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

AAD 2026 Preview: Late Breaking Data to Watch

Experts examine how the guidelines represent the evidence base for each step-up agent and address the limited role of laboratory testing in driving treatment decisions.

Interpreting the Treatment Algorithm: Evidence Levels, Diagnostic Workup, and the Stepwise Framework 

The updated international CSU guidelines updated its treatment algorithm to reflect newer treatment options, with a strong recommendation for omalizumab and conditional recommendations for dupilumab and remibrutinib. This difference does not imply that the newer agents are inferior in efficacy or unsuitable as first-choice step-up therapies — rather, it reflects the relative weight of evidence accumulated over time. Omalizumab has been studied for more than a decade in CSU, with well over 50 real-world studies complementing its pivotal trial data. Dupilumab and remibrutinib, as newer approvals, carry robust but comparatively smaller bodies of evidence. Clinicians should read the visual distinction as a commentary on the maturity of the data, not a directive about prescribing sequence. Patient-specific factors, including comorbidities, preferred route of administration, speed of desired onset, and payer access, appropriately influence agent selection at this step of the algorithm.

Laboratory testing in CSU plays a diagnostic-adjacent rather than treatment-directive role. The recommended baseline panel, which includes complete blood count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), total IgE, and thyroid peroxidase (TPO) antibody, is designed primarily to surveil for comorbid autoimmune conditions, most notably autoimmune thyroiditis, which occurs at elevated rates in CSU patients. These values do not inform the choice among omalizumab, dupilumab, and remibrutinib in the vast majority of cases; remibrutinib and dupilumab both work independently of IgE levels, further diminishing the utility of IgE testing as a treatment-selection tool. Clinicians should be explicit with patients about what these tests do and do not tell us: the CSU diagnosis is clinical, based on history and physical examination, and escalation decisions are not gated on laboratory findings.

In this video segment, Jasons Hawkes, MD, draws a clear distinction between diagnosis and management when addressing the testing framework, and Nicole Chase, MD, notes that she typically defers an extensive laboratory workup in straightforward presentations, reserving it for patients who are refractory to initial therapy or who present with features suggesting systemic disease. Both experts reaffirm that the stepwise framework — standard-dose antihistamines, then up-dosing to fourfold the approved dose, then step-up to a targeted agent — remains the structural backbone of the guidelines. The meaningful new development is the expanded menu at that third step, along with the flexibility extended to clinicians to individualize that choice based on the full clinical picture rather than defaulting to a single agent by convention.

Videos

Accelerated rTMS Matches Conventional Protocol in TRD, With Andrew Leuchter, MD

New data suggest that accelerated repetitive transcranial magnetic stimulation (rTMS) protocols may offer comparable efficacy to conventional treatment schedules for patients with 

, while substantially reducing treatment burden.

 In an interview with HCPLive, Andrew Leuchter, MD, a professor and director of the neuromodulation division at UCLA TMS Clinical and Research Service, discussed findings from a recent retrospective analysis comparing a 5 × 5 accelerated rTMS protocol (5 sessions per day over 5 days) with standard once-daily treatment delivered over 6 weeks.

For clinicians managing TRD, the takeaway is straightforward: rTMS remains a highly effective noninvasive neuromodulation option, even among patients who have failed multiple pharmacologic trials. However, traditional delivery schedules, requiring daily clinic visits for up to 2 months, have historically limited uptake due to logistical challenges and patient burden.

“The importance of this study that we just published is that it shows that it's not necessary to have patients come in daily for 6 or 8 weeks, that we can actually compress the entire course of TMS treatment down to just 1week, with giving patients multiple treatment sessions per day, and that this accelerated TMS treatment can be as effective or more effective than the traditional one's daily treatment,” Leuchter said.

The study evaluated 175 patients with major depressive disorder (MDD), comparing outcomes between 40 patients treated with accelerated 5 × 5 protocols and 135 patients receiving conventional once-daily rTMS. Both approaches produced significant improvements in depressive symptoms, with no statistically significant difference in overall efficacy (

 =.07). Mean PHQ-9 scores decreased from 17.68 to 10.98 in the accelerated group and from 17.83 to 8.97 in the conventional group at treatment completion.

From a practical standpoint, accelerated rTMS offers a compelling advantage in terms of access and adherence. Compressing a full course of treatment into a single week may reduce disruptions to work, caregiving responsibilities, and daily functioning, which are factors that often contribute to nonadherence in conventional protocols.

However, financial considerations remain a critical barrier. Conventional once-daily rTMS is widely covered by insurance, whereas accelerated protocols are typically not reimbursed, requiring out-of-pocket payment. As Leuchter noted, this creates a clear tradeoff: accelerated treatment may be more feasible from a time perspective but less accessible from a cost standpoint.

Another clinically relevant finding from the study relates to the timing of treatment response. While some patients undergoing accelerated rTMS experienced rapid improvement within the 5-day treatment window, a substantial subset showed minimal early response. Follow-up data demonstrated that many of these initial non-responders achieved significant symptom improvement within 2 to 4 weeks post-treatment. Among the lower-response subgroup, improvement increased from 8% at day 5 to 36% at follow-up (

“Going into treatment, this is something I tell all our patients. I say, ‘At the end of 5 days, I'm going to talk with you. We'll see how you're doing. If you're not feeling [the] benefit, don't be disappointed. I'll talk to you again in 2 weeks, and at that point, the benefits will almost certainly have started to kick in,” Leuchter said. “It's important to let patients know that upfront to temper their expectations on how quickly they’re going to recover.”

Accelerated deep TMS has also gained attention recently. On March 17, 2026, Radial announced that a study found accelerated deep TMS, delivered over 6 days, achieved clinically comparable outcomes to standard multi-week treatment in patients with MDD.

 The SWIFT protocol cut sessions from 36 to 6 half-days.

Participants in the SWIFT arm received 5 ACC-iTBS (110% rMT, H1 coil) sessions per day for 6 days, plus 1 day per week with 2 sessions for 4 weeks. Accelerated and standard sessions yielded comparable response rates (87.8% vs 87.5%).

“Deep TMS is another form of TMS that uses a much larger electromagnet... It stimulates a much larger area of the brain surface, and it looks like deep TMS can be very effective for many patients,” Leuchter said. “There have been a few head-to-head studies, and both conventional TMS and deep TMS seem to work very well for the great majority of patients; there does not appear to be a lot of difference in effectiveness between the two types of stimulation. Some patients may do better with one or the other.”

A reported disclosure for Leuchter includes Abbott Laboratories.

Apostol MR, Valles TE, Corlier J, et al. Efficacy of 5 × 5 accelerated versus conventional repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant depression. 

Derman C. Accelerated Deep TMS Matches Standard Outcomes in TRD in 6 Days. HCPLive. Published March 18, 2026. Accessed on March 18, 2026. 

https://www.hcplive.com/view/accelerated-deep-tms-matches-standard-outcomes-trd-6-days

Accelerated 5×5 rTMS delivers comparable outcomes to standard protocols, offering faster treatment with key tradeoffs in cost, access, and response timing.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Experts discuss how clinicians can use patient preferences, comorbidities, route of administration, and access considerations to guide decisions.

Individualized Therapy Selection: Shared Decision-Making Among Omalizumab, Dupilumab, and Remibrutinib 

The selection of a step-up agent in CSU should be driven by a shared decision-making framework that accounts for disease severity, patient preferences regarding route of administration, comorbid conditions, age (remibrutinib is indicated for adults only; dupilumab is approved for patients aged 12 and older), and access. No evidence-based algorithm currently dictates that 1 of the 3 agents, namely omalizumab, dupilumab, or remibrutinib, should be universally preferred in the absence of specific patient characteristics, and no agent is universally superior. Comorbid type 2 inflammatory conditions represent 1 of the clearer clinical signals for preferring dupilumab; patients with concurrent atopic dermatitis, asthma, eosinophilic esophagitis, or chronic rhinosinusitis with nasal polyps may obtain disease-modifying benefit across conditions from a single biologic. Conversely, patients who prioritize the established long-term safety profile and longest real-world track record may opt for omalizumab, while those who require speed of onset or prefer an oral formulation have a compelling case for remibrutinib.

Practical access and initiation logistics represent underappreciated determinants of real-world treatment outcomes. The cost of all 3 agents is substantial, and the agent a patient can realistically obtain, through insurance approval, patient assistance programs, or sample availability, may be the most important factor in the initial prescribing decision. Sample availability for remibrutinib has proven particularly useful for initiating therapy quickly, bypassing the authorization delays that can accompany biologic prescriptions and reducing the "activation energy" barrier that prevents some patients from starting a new therapy. Clinicians should also recognize that patients who fail or have suboptimal responses to 1 agent can be transitioned to another with a different mechanism of action — and communicating this explicitly to patients at the time of initial prescribing supports adherence by framing the treatment pathway as iterative rather than all-or-nothing.

In this video segment, Jason Hawkes, MD, describes his approach as laying out the clinical landscape and letting the patient choose, identifying several patient archetypes that may favor specific agents: those already managing multiple oral medications may prefer remibrutinib for ease of integration; needle-averse patients may similarly gravitate toward the oral formulation; and patients or family members already familiar with dupilumab from its use in other approved indications may approach it with reduced hesitancy. Nicole Chase, MD, characterizes this moment in CSU management as the arrival of "choose-your-own-adventure" pathways, emphasizing that the economics of patient preference, whether defined by time, convenience, cost, or comfort, should be central to every step-up therapy conversation. Both experts agree that getting patients onto any 1 of the 3 agents is clinically preferable to prolonged deliberation, and that the availability of alternatives reduces the stakes of any single initial choice.

Individualized Therapy Selection: Shared Decision-Making Among Omalizumab, Dupilumab, and Remibrutinib

Finerenone Expands CKD Treatment Beyond Diabetes: FIND-CKD Insights

New findings from the FIND-CKD trial suggest Bayer’s finerenone (Kerendia) may have a broader role in chronic kidney disease (CKD) than previously established, extending benefits beyond patients with diabetes and into a wider range of non-diabetic kidney diseases.

The phase 3 trial met its primary endpoint for statistically significant improvement in eGFR slope versus placebo over 32 months in adult patients with nondiabetic CKD. Bayer described plans to use these data to support a label expansion into this patient population.

Finerenone first received FDA approval in 2021 for adults with CKD associated with type 2 diabetes based on findings from the FIDELIO-DKD and FIGARO-DKD trials, which established the agent's ability to reduce risk of cardiovascular death, hospitalization for heart failure, non-fatal myocardial infarction, sustained eGFR decline, and end-stage kidney disease in patients with diabetic kidney disease. It was later approved for heart failure with left ventricular ejection fraction of 40% or higher in July 2025 and is additionally seeking regulatory approval for patients with type 1 diabetes and CKD based on data from the FINE-ONE trial.

The randomized, double-blind, placebo-controlled, phase 3 FIND-CKD study enrolled more than 1500 adults with non-diabetic CKD, including patients with hypertension-related disease and chronic glomerulonephritis. Results showed finerenone demonstrated superiority over placebo in slowing kidney function decline, meeting its primary endpoint based on total eGFR slope over 32 months.

“What this suggests, and we'll have to look at the data carefully, is that finerenone is likely to play an important role in reducing the risk of kidney disease progression in a much broader range of patients than it is currently being used for,” Brendon Neuen, MBBS, PhD, told 

The implications extend beyond a single therapy. As evidence accumulates, the traditional “4 pillars” of CKD management initially established in diabetic kidney disease are increasingly being applied across the CKD spectrum. This includes renin-angiotensin system inhibitors, SGLT2 inhibitors, and now nonsteroidal mineralocorticoid receptor antagonists like finerenone.

For clinicians, this shift underscores the urgency of earlier detection. With more therapies capable of altering disease trajectory, Neuen says timely screening and diagnosis are becoming more critical than ever.

“There is an urgency like we haven't had before to identify people early, screen people for kidney disease, diagnose them appropriately, and treat them with evidence-based therapies,” he said.

At the same time, treatment strategies are evolving toward a multimodal approach, with multiple therapies now available to reduce kidney and cardiovascular complications. Because kidney disease progression is complex and involves many drivers, experts are increasingly recognizing that many patients will require treatment with multiple highly effective therapies. According to Neuen, finerenone is likely to be an important part of that armamentarium.

Looking ahead, Neuen highlighted the importance of precision medicine using validated risk tools to better identify patients who would benefit from intensified therapy and the continued development of targeted treatments, particularly for glomerular diseases. Together, these advances signal a shift toward more individualized, mechanism-based care in CKD.

Editors’ Note: Relevant disclosures for Neuen include AstraZeneca, Bayer, Boehringer and Ingelheim, Janssen, and others.

Campbell P. Finerenone Proves CKD Benefit Extends Beyond Diabetes in FIND-CKD. HCPLive. March 16, 2026. Accessed March 18, 2026. 

https://www.hcplive.com/view/finerenone-proves-ckd-benefit-extends-beyond-diabetes-in-find-ckd

Campbell P. FINE-ONE: Finerenone Proves Benefit in Type 1 Diabetes and CKD. HCPLive. November 6, 2025. Accessed March 18, 2026. 

https://www.hcplive.com/view/fine-one-finerenone-proves-benefit-in-type-1-diabetes-and-ckd

Neuen reflects on new FIND-CKD data suggesting finerenone’s benefit in nondiabetic chronic kidney disease and highlights urgency of early screening and combination therapy.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Expanding the Role of Finerenone in CKD Care, With Brendon Neuen, MBBS, PhD

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Podcasts

ATTD 2026 reveals AI “digital twins,” next-gen closed-loop pumps, and sensors that boost time-in-range and ease diabetes management.

Type 1 Diabetes

Type 2 Diabetes

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue: ATTD 2026 Recap

This Q&A highlights Dr. Alexa B. Kimball's responses to questions on the FDA approval of secukinumab for pediatric patients with hidradenitis suppurativa (HS).

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Reflecting on FDA Approval of Secukinumab for HS in Children, With Alexa Kimball, MD, MPH

Christine Limonte is an assistant professor at UW Medicine and a study investigator for the Kidney Precision Medicine Project.

Data from 39 kidney biopsies may challenge longterm beliefs about diabetic nephropathy in CKD.

Kidney Biopsies Challenge Diabetic Nephropathy Diagnoses in CKD, With Christine Limonte, MD

Corey Cavanaugh, DO, is an academic nephrologist at the Cleveland Clinic. 

In a rapidly evolving therapeutic landscape, how can clinicians make decisions to personalize IgAN care?

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Who Gets What, When? Navigating Therapy Selection in IgA Nephropathy, With Corey Cavanaugh, DO

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The MiniMed Flex is a discreet, smartphone-controlled insulin pump that is roughly the size of 2 stacked insulin vials.

FDA News

FDA Clears MiniMed Flex, A Smaller and Smartphone-Controlled Insulin Pump

Viet Le, DMSc, PA-C, is a preventive cardiology PA at Intermountain Health and the former president of the Academy of Physician Associates in Cardiology.

Le discusses the AHA/ACC clinical guidelines for the management of dyslipidemia, highlighting the shifting attitude towards hypertriglyceridemia treatment.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

Atherosclerotic Cardiovascular Disease

Strategic Alliance Partnership

ACC/AHA Dyslipidemia Guidelines Refocus Hypertriglyceridemia Treatment, With Viet Le, DMSc, PA-C

This discussion reflects on great speakers, the unique pressures women face on the podium, and what it takes to build a national platform in academic medicine.

Networking, Niches, and Why Authenticity Is Your Biggest Career Asset in Dermatology

Andrea Kossler, MD, describes her multidisciplinary co-management model with ophthalmologists and outlines a forward-looking vision for earlier diagnosis, precision medicine, and optimized surgical integration in thyroid eye disease.

Video Series

Combination Strategies, Multidisciplinary Care, and the Future of TED Management

Andrea Kossler, MD, explores the management of thyroid eye disease in special populations, emerging IGF‑1R agents and alternative targets such as interleukin 6 (IL‑6) and FcRn, and the potential role of serologic biomarkers in predicting response and relapse.

Special Populations, Emerging Targets, and Biomarkers

Andrea Kossler, MD, reviews the current therapeutic armamentarium for moderate to severe thyroid eye disease, including corticosteroids, teprotumumab, radiotherapy, and orbital decompression surgery, and discusses how these therapies fit into contemporary practice.

Latest News

AAD 2026 Preview: Late Breaking Data to Watch

Interpreting the Treatment Algorithm: Evidence Levels, Diagnostic Workup, and the Stepwise Framework

Accelerated rTMS Matches Conventional Protocol in TRD, With Andrew Leuchter, MD

Individualized Therapy Selection: Shared Decision-Making Among Omalizumab, Dupilumab, and Remibrutinib

Expanding the Role of Finerenone in CKD Care, With Brendon Neuen, MBBS, PhD